日期: 2026 年 3 月 25 日

CLEVELAND, Ohio, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, announced the implementation of a transportation surcharge to address continued cost escalation across the Americas freight and logistics market. Beginning April 1, 2026, a $350 per delivery surcharge will apply to all shipments.The freight and logistics market continues to experience elevated costs driven by rising diesel prices, evolving regulatory requirements affecting driver availability, tighter trucking capacity, and increasing operating expenses across the logistics sector. Industry forecasts indicate these pressures will persist for the foreseeable future."Maintaining reliable service for our customers requires us to adapt to sustained shifts in the transportation landscape," said Tom Kelly, Formerra CEO. "This surcharge is necessary to address these industrywide cost pressures that are outside of our control while continuing to provide the high service levels customers expect from Formerra."Customers should contact their Formerra representative for more information.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisFormerraMarketing Communications Managerjackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

俄亥俄州克利夫蘭, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 高性能材料分銷領域的領導者 Formerra 宣布將實施運輸附加費，以因應美洲貨運與物流市場持續攀升的成本。自 2026 年 4 月 1 日起，所有貨件將適用每筆運送 350 美元的附加費。受柴油價格上漲、影響司機供應的監管要求變化、卡車運輸運力趨緊，以及物流業整體營運成本攀升等因素驅動，貨運與物流市場持續面臨成本高企的困境。業界預測顯示，這些壓力在可預見的未來將持續存在。「為維持對客戶的可靠服務，我們必須適應運輸環境的持續變革，」Formerra 執行長 Tom Kelly 表示。「這項附加費是必要的，旨在應對這些超出我們控制範圍的業界成本壓力，同時持續提供客戶對 Formerra 所期待的高水準服務。」客戶如需更多資訊，請聯繫您的 Formerra 業務代表。關於 FormerraFormerra 是工程材料領域的頂尖分銷商，串聯全球領先的聚合物生產商與醫療保健、消費品、工業及移動出行市場中的數千家原始設備製造商（OEM）和品牌所有者。憑藉技術與商業專業知識，Formerra 融合了產品組合深度、供應鏈實力、產業知識、服務品質、領先的電子商務能力以及創新思維，形成獨特的優勢組合。Formerra 經驗豐富的團隊協助各產業客戶以嶄新且更佳的方式進行產品設計、選材、加工與開發，從而提升產品性能、生產力、可靠性及永續性。欲了解更多資訊，請造訪 www.formerra.com 。媒體聯絡人Jackie MorrisFormerra行銷傳播經理 jackie.morris@formerra.com+1 630-972-3144消息來源：Formerra Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Toronto, ON, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, has introduced a new data layer within its Personal Wellness Account, designed to enhance how its AI assistant interprets and structures wellness data.As part of its ongoing product development, Aleen Inc. has implemented a biomarker extraction approach that enables the system to process user-provided data and identify key indicators in a more structured way. This includes the use of a dedicated AI agent that processes documents page by page and extracts relevant biomarkers from wellness data sources.In addition to extraction, Aleen Inc. is developing a standardized structure for each biomarker, including its name, value, unit of measurement, and reference range. These structured data elements are now reflected within the Personal Wellness Account interface. Users will be able to view the total number of detected biomarkers and potential deviations directly within the file list, while a dedicated “Biomarkers” tab in the detailed view provides expanded access to the data in both table and panel formats, along with search and filtering capabilities.This development represents a step toward more structured data environments within Aleen’s ecosystem, supporting improved organization, accessibility, and interaction with wellness data. The introduction of this layer may also contribute to future enhancements in how the system identifies patterns and supports user-centered insights. This update reflects Aleen Inc.’s continued focus on building scalable data architecture and advancing its Personal Wellness Account as a structured, AI-assisted environment for working with wellness data.About Aleen Inc.Aleen Inc. operates as a digital wellness and well-being insights company. Its platform transforms personal wellness information into simple, personalized insights that promote greater self-awareness and balance in daily life. Aleen’s mission is to empower individuals with knowledge and clarity through responsible use of technology and data.For more information, visit www.aleen.ca.Forward-Looking StatementThis press release contains forward-looking statements regarding future plans and developments by Aleen Inc. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Aleen Inc. undertakes no obligation to update or revise these statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.69% to RMB 7.71 billion.Innovation remained the engine of Hengrui’s growth: Innovative drug sales increased by 26.09% year-on-year to RMB 16.34 billion, contributing 58.34% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.52% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.36% YoY).Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.58% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for Class 1 innovative drug, one for a Class 2 innovative drug, and six for new indications of marketed innovative drugs. The pace of regulatory progress accelerated with 15 NDA/BLAs accepted by the NMPA. Meanwhile, 28 drug candidates entered Phase III clinical trials, 61 progressed to Phase II, and 28 NMEs entered Phase I for the first time.The company currently has over 100 proprietary innovative products in clinical development and is conducting more than 400 clinical trials. This robust portfolio will be further supported by approximately 53 innovative product and indication approvals anticipated during 2026-2028.2025 marked another year of accelerated progress in Hengrui's global expansion. Licensing revenue rose 25.62% to RMB 3.39 billion, cementing the growing global recognition and value of the company’s innovative portfolio. During the year, the company completed five overseas business development transactions for innovative drugs with leading MNCs and biotechs, highlighted by a strategic collaboration with GSK. In parallel, the company continued to advance its self-developed assets and global regulatory efforts. Multiple innovative drugs had their first global clinical trials initiated, ranging from Phase I to III.Additionally, Hengrui successfully listed on the Hong Kong Stock Exchange, raising total gross proceeds of HK$11.4 billion (US$1.5 billion), including the over-allotment option — marking the largest pharmaceutical IPO in Hong Kong in the past five years and further strengthening its access to global capital.Looking ahead, Hengrui will continue to focus on addressing unmet clinical needs with its differentiated innovative portfolio, placing equal emphasis on independent R&D and open collaboration to expand access to innovative drugs for patients worldwide.About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.Forward-Looking StatementsThis press release contains forward-looking statements, including statements about the company's future growth prospects and pipeline potential. These statements are based on current expectations and assumptions and do not guarantee future performance. Actual results, developments, and business decisions may differ materially from these forward-looking statements. All information in this press release is as of the date of this press release, and Hengrui undertakes no duty to update such information unless required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 3月25日，恒瑞醫藥發佈2025年年度報告。報告期內，公司堅持「科技創新+國際化」雙輪驅動戰略，實現業績持續增長，營收和淨利均再創新高。全年實現營業收入人民幣316.29億元，同比增長13.02%；歸屬於上市公司股東的淨利潤77.11億元，同比增長21.69%；歸屬於上市公司股東的扣除非經常性損益的淨利潤74.13億元，同比增長20.00%。創新藥銷售收入163.42億元，同比增長26.09%，佔藥品銷售收入比重達58.34%；對外許可收入33.92億元，同比增長25.62%。在業績持續增長的同時，公司保持高强度研發投入，全年累計研發投入87.24億元，佔營業收入的27.58%，其中費用化研發投入69.61億元，為發展築牢創新根基。創新成果轉化高效賦能，創新藥銷售引領業績增長創新藥銷售收入中，抗腫瘤産品收入132.40億元，同比增長18.52%，佔整體創新藥銷售收入的81.02%。醫保內創新藥瑞維魯胺（二代AR拮抗劑）、達爾西利（CDK4/6抑制劑）精準定位未被滿足的臨床需求，優異的臨床數據在診療實踐中得到廣泛驗證，銷售收入繼續保持强勁增長。氟唑帕利（PARP抑制劑）、海曲泊帕（TPO受體激動劑）等上市較早的創新藥，隨著新適應症的持續獲批或上市後研究循證醫學證據的逐步積累，持續為公司銷售收入注入穩定增量。伊立替康脂質體（TOP1）、瑞康曲妥珠單抗（HER2 ADC）等産品雖處於商業化初期，報告期內尚未納入醫保，但憑藉針對特定患者的明確療效優勢，通過高效的上市前準備與市場准入策略，有力驅動了産品前期的快速放量。創新藥銷售收入中，非腫瘤産品實現收入31.02億元，同比增長73.36%，佔整體創新藥銷售收入的18.98%。恒格列淨（SGLT2抑制劑）、瑞馬唑侖（GABAa受體激動劑）等醫保內産品通過臨床優勢的有效傳遞，實現較快增長。新藥新適應症持續獲批，三年內約53款創新成果蓄勢待發2025年，公司持續加大創新力度。報告期內，公司上海創新研發中心正式啓用，進一步完善公司研發體系。公司持續建設行業領先的新技術平台，加强源頭創新。報告期內，公司不斷完善已建立成熟的ADC、雙/多抗、蛋白降解劑、小核酸藥物、口服多肽、PROTAC/分子膠/RIPTAC等技術平台，初步建成新分子模式平台。同時，恒瑞大力發展人工智能藥物發現（AIDD），全面賦能藥物研發的創新與迭代。公司已形成行業領先且高度差異化的創新産品矩陣。目前，公司已在中國獲批上市24款1類創新藥、5款2類新藥，另有100多個自主創新産品正在臨床開發，400餘項臨床試驗在國內外開展。2025年，公司（含報表內子公司）7款1類創新藥獲批上市，包括注射用瑞卡西單抗、硫酸艾瑪昔替尼片、瑞格列汀二甲雙胍片(I)(II)、注射用瑞康曲妥珠單抗、蘋果酸法米替尼膠囊、注射用磷羅拉匹坦帕洛諾司瓊、澤美妥司他片等； 1款2類創新藥獲批上市，6個已獲批創新藥的新適應症獲批上市，涵蓋腫瘤、代謝、心血管、免疫、神經科學等疾病領域。報告期內公司研發管綫顯著進展，共有15項上市申請獲NMPA受理，28項臨床推進至III期，61項臨床推進至II期，28項創新産品首次推進至臨床I期。2025年，公司取得藥物臨床批件180個；獲得CDE突破性治療品種認定8項，優先審評品種認定2項。此外，2025年公司招募了22,000餘名參與者參加臨床研究，自有的臨床開發實力使公司能夠高效推進産品的監管評審進度。專利申請和維持工作順利開展。報告期內，獲得大中華地區授權76件、國外授權209件。截至報告期末，擁有大中華區授權發明專利986件，歐美日等國外授權專利1,021件。2025年，恒瑞醫藥共有20款産品／適應症通過新版國家醫保目錄調整，其中10款産品首次進入醫保，不斷提升優質藥物的可及性與可負擔性，也有助於加速産品放量，提升市場份額，進一步鞏固公司在創新藥領域的領先地位。未來成長性方面，公司增長潛力有望進一步釋放。根據公告，2026-2028年預計約有53項創新成果獲批上市。其中，新品上市方面，具備同類最佳潛力的GLP-1/GIP雙受體激動劑HRS9531用於超重／肥胖有望獲批。在新適應症獲批方面，瑞康曲妥珠單抗有望獲批用於HER2陽性結直腸癌、HER2陽性乳腺癌一綫治療等多個新適應症。國際化提速，BD成業績增長新引擎雄厚的創新研發實力，為公司高水平的國際化合作奠定了堅實基礎。2025年，恒瑞醫藥BD合作模式持續創新，共達成5筆創新藥海外業務拓展交易。其中與GSK達成戰略聯盟尤為矚目：雙方共同開發包括PDE3/4抑制劑HRS-9821在內的至多12款創新藥，恒瑞獲得5億美元首付款，潛在總金額約120億美元的選擇權行使費和里程碑付款及相應的銷售提成，彰顯對恒瑞創新平台與研發實力的深度認可。與MSD就Lp(a)抑制劑HRS-5346達成大中華區外獨家許可，2億美元首付及最高17.7億美元里程碑付款，進一步驗證全球競爭力。此外，口服GnRH拮抗劑SHR7280中國大陸商業化權益授權Merck KGaA，Myosin小分子抑制劑HRS-1893以NewCo模式授權Braveheart Bio，瑞康曲妥珠單抗部分國際市場權益授權Glenmark。自2023年起公司已完成12筆海外業務拓展交易，包括對外許可、NewCo和戰略聯盟等不同模式，潛在總交易價值超過270億美元。這一系列活躍的BD交易，正加速推動恒瑞創新藥的全球價值兌現。與此同時，恒瑞也在積極推進海外自主開發及註册。報告期內，公司新開設美國波士頓臨床研發及合作中心。目前，公司在亞洲、歐美及澳大利亞設立15個研發中心，報告期內多個創新藥啟動首項海外臨床試驗。此外，報告期內，HER2 ADC創新藥瑞康曲妥珠單抗聯合阿得貝利和化療用於胃癌或胃食管結合部腺癌獲美國FDA孤兒藥資格認定。目前公司共有5款創新藥獲FDA孤兒藥資格認定，4款ADC産品獲FDA快速通道資格認定。此外，報告期內公司成功登陸港交所實現「A+H」上市，募集資金113.74億港元，為近5年港股醫藥板塊最大IPO，國際化邁向新的里程碑。2025年，公司積極探索創新治療方案，向世界展現「中國藥」的臨床價值。報告期內已有與公司産品相關的381項重要研究成果獲得國際認可。相繼在CA（臨床醫師癌症雜誌）、The Lancet（柳葉刀）、JAMA（美國醫學會雜誌）等全球頂級期刊發表，累計影響因子達3,159分，包括18篇重磅研究論文（腫瘤領域影響因子≥30分、非腫瘤領域影響因子≥20分的國際期刊）。公司在全球學術舞台的參與維度也再上新台階。腫瘤領域，2025年有72項、46項研究分別入選ASCO年會、ESMO年會，並首次以展台形式登陸ESMO；非腫瘤領域多項成果被美國糖尿病協會（ADA）年會、美國皮膚科學會（AAD）、歐洲腎臟協會大會（ERA）等國際會議錄用為口頭報告。構建全球化人才梯隊，運營管理全面升級國際化戰略的深化，離不開全球化組織能力的支撑。2025年，公司深化引智育才，構建全球化人才梯隊。聘請馮佶女士加盟並出任公司總裁，强化全球戰略領導力；聘請朱國新先生為公司高級副總裁、全球早研負責人，强化管綫的前瞻佈局與源頭創新；聘請尹航先生為公司副總裁、腫瘤事業部總經理，持續强化腫瘤領域競爭力；聘請Yu Liu先生為國際首席醫學官，負責推動在美國及中國以外地區的臨床開發工作；聘請Karen Atkin女士擔任國際商業和組合策略負責人，進一步加强海外商業拓展。同時，通過「全球精英計劃」廣泛吸引來自全球頂尖院校與科研機構的優秀學生及青年學者加入。內部培養方面，針對不同層級的關鍵人才，系統性實施「中高層高潛人才400發展項目」、「新晋管理者訓練營」及「恒瑞領導力峰會」等培養計劃，全力打造專業、年輕、國際化的一流人才梯隊。公司持續强化戰略與組織適配，2025年新成立生物製藥事業部（BBU），與原有腫瘤事業部（OBU）齊頭並進，通過組織升級來提升領先的商業化能力。公司形成商業卓越、市場營銷、醫學事務、中央及省級銷售管理、中央及省級市場准入等互補職能體系賦能專業銷售隊伍。公司建立了廣泛而深入的全渠道覆蓋網絡。目前，公司的銷售網絡遍佈全國超過25,000家醫院及超過200,000家綫下零售藥店。此外，公司設立基層廣闊市場架構，根據市場潛力和産品屬性，對廣闊市場佈局進行升級。截至目前，公司社區終端覆蓋已突破2,500家，累計開展學術活動覆蓋醫生2萬人次，基層品牌影響力顯著提升。深化政産學研融合，踐行可持續承諾為進一步强化公司在生物醫藥領域的基礎研究能力，公司積極推動政産學研聯動，與國家自然科學基金委員會聯合成立「國家自然科學基金民營企業創新發展聯合基金」，總計1.32億元，重點圍繞腫瘤、代謝性疾病等方向開展基礎或應用基礎研究。此外，與中國科技發展基金會簽署戰略合作備忘錄，將出資1億元人民幣，用於資助科技創新、資源賦能、人才培育、國際交流等七大領域的項目，携手推動科技創新和産業創新深度融合。同時，作為中國醫藥創新的領軍企業，恒瑞醫藥始終重視履行社會責任，深度踐行可持續發展理念。2025年11月，香港大埔宏福苑發生嚴重火災，災情引發社會各界深深關切。恒瑞醫藥宣佈緊急捐贈1000萬港元，用於緊急救援以及災後重建等工作。憑藉在醫藥創新、合規運營、綠色發展及社會責任等領域的優異表現，恒瑞醫藥在國際權威指數機構明晟（MSCI）ESG評級躍升至「AA」級，躋身全球製藥行業前列。憑藉創新、國際化高質量發展的成果，恒瑞醫藥屢獲國內外權威認可。連續7年上榜美國製藥經理人雜誌公佈的全球製藥企業TOP50榜單；根據2025年Citeline 發佈的管綫規模排名，公司自研管綫規模位居全球第二； 成功躋身財富中文網發佈的2025年《財富》中國500强； 海曲泊帕乙醇胺片（恒曲®）專利榮獲中國專利金獎；恒瑞醫藥還連續5年榮膺「中國傑出僱主」認證，人力資源管理領域成就再獲肯定。未來，恒瑞醫藥將繼續秉持「科技創新+國際化」雙輪驅動戰略，深耕臨床未滿足需求，打造差異化創新産品；堅持自主研發與開放合作並重，為全球患者帶來更多、更好的治療選擇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Everbright Grand China Assets Limited, a property leasing, property management and sales of properties held for sale company under China Everbright Group ("Everbright Grand China Assets" or the "Group", Hong Kong Stock Exchange stock code: 3699) today announced the annual results for the year ended 31 December 2025 (the "Year under Review").During the Year under Review, the Group's revenue was approximately RMB49.9 million (2024: approximately RMB45.9 million), representing a increase of approximately 8.7% as compared to last year, mainly attributable to the increase in total rental income from investment properties. The profit attributable to equity shareholders of the Company amounted to approximately RMB19.5 million (2024: approximately RMB25.3 million), representing an decrease of approximately 22.9% as compared to last year. The decrease in profit was primarily due to the increase in dividend withholding tax and deferred tax expenses recognised in 2025. The Board has proposed to pay a final dividend of RMB1.04 cents per share for the year ended 31 December 2025 (2024: RMB1.05 cents). Together with the interim dividend of RMB0.73 cents per share, the full year dividend amounts to RMB1.77 cents per share (2024: RMB2.17 cents per share).As at 31 December 2025, the Group had current assets of approximately RMB241.0 million (2024: approximately RMB239.9 million). The increase in current assets was mainly a result of [the increase in deposits with maturity of more than three months and cash and bank balances during the year].. The Group had current liabilities of RMB20.1 million (2024: approximately RMB19.9 million). The increase in current liabilities was mainly due to he rise in lease liabilities arising from lease renewals.Property LeasingDuring the year under Review, the rental income from the Group’s property leasing business was approximately RMB34.0 million for the year ended 31 December 2025 (2024: RMB30.5 million). Due to increase in the average rent per square metre, and together with rental subsidies offered to tenants, the total rental income increase. As at 31 December 2025, the Group’s property portfolio comprises three commercial buildings, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building, with a total gross floor area (“GFA”) of approximately 89,507 square meters.Property Management ServiceThe Group provides property management services for its properties, namely Everbright Financial Center and Everbright International Mansion. Revenue from the Group’s property management services was approximately RMB15.9 million for the year ended 31 December 2025 (2024: RMB15.4 million). The increase in revenue from property management services was due to the increase in restaurant income. As at 31 December 2025, the total GFA under the Group’s management was 72,534 sq.m.Investment PropertiesThe Group's investment properties primarily consist of land and/or buildings which are owned or held under a leasehold interest to earn rental income and/or for capital appreciation. As at 31 December 2025, the fair value of the investment properties was RMB979.0 million (2024: RMB967.1 million), representing an increase of approximately 1.23%. For the year ended 31 December 2025, the valuation gain on investment properties amounted to approximately RMB10.3 million (2024: approximately RMB6.6 million).PROSPECTSAs the World Bank noted that despite persistent trade tensions, the global economy has demonstrated stronger-than-expected resilience. Amid a complex environment of mounting external pressures and internal challenges, China continued to advance high-quality development, with the overall economy maintaining stable performance and achieving steady progress. With stable economic growth, corporate demand for commercial space has increased. Coupled with accelerated urbanization and the development of new business districts, demand for commercial properties has continued to rise, supporting the growth of commercial property management and leasing activities. In addition, the Chinese government has introduced a series of favourable policies for the commercial real estate sector, focusing on inventory digestion and optimization of industry planning, thereby providing further support to the property management and leasing industry.The Group’s managed properties mainly comprise commercial assets. Despite macroeconomic conditions and market competition, tenancy arrangements, lease agreements and occupancy rates remained stable in 2025. However, rental levels for newly signed leases were lower than in previous periods. To mitigate the pressure arising from rental adjustments, the Group will continue to enhance customer satisfaction by incorporating value-added services into new lease agreements, including property maintenance and upkeep, facilities management and community event planning.The Group’s existing properties are primarily located in Chengdu, Sichuan and Kunming, Yunnan—two key regional cities—and comprise three commercial buildings: Everbright Financial Center, Everbright International Mansion and Ming Chang Building. Benefiting from their prime locations and high-quality facilities, these properties have attracted a sizable number of state-owned enterprises and large institutions, providing a solid foundation for the Group’s leasing business. In recent years, the Group has successfully introduced tenants from emerging sectors such as software and technology, while also offering digitalised services to tenants. Looking ahead, the Group will continue to promote diversified business development and strive to attract more high-quality commercial tenants.In addition, the further escalation of the situation in the Middle East in March 2026 has led to rising energy prices, heightened inflation expectations and slower economic growth, all of which are core factors affecting overseas investment decisions. Accordingly, the Group will carefully reassess its asset allocation and regional risks with respect to its overseas investment plans. Despite the current significant volatility in the global economy, the Group will adhere to the principle of prudent operation, flexibly seize investment windows, and ensure the safety of capital operations.The Group continues to leverage technology to advance smart property management, enhance operational efficiency and elevate the customer experience. By strengthening digitalisation and refined management capabilities, the Group aims to further improve service quality and customer satisfaction.By fully leveraging the synergy with its parent company, China Everbright Group, while actively developing diversified value-added services to broaden its revenue mix and enhance brand influence. As the industry undergoes transformation and upgrading, the Group remains committed to prudent operations, a strong focus on risk management and internal controls, agile responses to macroeconomic and policy developments, continuous optimisation of its asset portfolio, further strengthening of its resilience against market uncertainties, and also actively explore new development opportunities to create greater value for the shareholders.About Everbright Grand China Assets LimitedEverbright Grand China Assets Limited is engaged in the businesses of property leasing and the provision of property management services under China Everbright Group. It owns, leases and manages properties located in Chengdu, Sichuan province, and also owns and leases a property located in Kunming, Yunnan province. The Group's properties are located in the city centers of Chengdu and Kunming, the key cities of western China. The Group's property portfolio includes three commercial properties, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building. For more information about Everbright Grand China Assets, please visit the Company’s website: https://ebgca.com.hk/.This press release is issued by Porda Havas International Finance Communications Group on behalf of Everbright Grand China Assets Limited.For inquiries, please contact: Kelly Fung+852 2590 1900kelly.fung@pordahavas.co Qin Luk+852 2590 1903samantha.luk@pordahavas.comEmail: ebgca.hk@pordahavas.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 光大永年（03699.HK）今天公佈截至2025年12月31日止年度（「回顧年度」）之全年業績。回顧年度，本集團的收益約為人民幣49.9百萬元（2024年：約人民幣45.9百萬元），較去年增加約8.7%，主要由於投資物業的租金總額增加所致。本公司權益股東應佔利潤約為人民幣19.5百萬元（2024年：約人民幣25.3百萬元），較去年減少約22.9%。利潤減少主要由於於2025年確認的股息預扣稅及遞延稅項增加。每股基本盈利約為人民幣4.42分（2024年：人民幣5.72分）。董事會建議就截至2025年12月31日止年度派付末期股息每股人民幣1.04分（2024年：人民幣1.05分）。連同中期股息每股人民幣0.73分，全年股息為每股人民幣1.77分（2024年：每股人民幣2.17分）。於2025年12月31日，本集團的流動資產約為人民幣241.0百萬元（2024年：約人民幣239.9百萬元）。流動資產增加主要由於年內到期日超過三個月的存款增加及現金及銀行結餘上升所致。。本集團的流動負債為人民幣20.1百萬元（2024年：約人民幣19.9百萬元）。流動負債增加主要是由於續約租賃負債的增加所致。物業租賃回顧年度，本集團物業租賃業務的租金收入約為人民幣34.0百萬元（2024年：人民幣30.5百萬元）。2025年新增租戶使總租金收入增加。於2025年12月31日，本集團的物業組合包括三棟商業樓宇，即光大金融中心、光大國際大廈的部分物業及明昌大廈的部分物業，總建築面積約為89,507平方米。物業管理服務本集團為其物業（即光大金融中心及光大國際大廈）提供物業管理服務。回顧年度，本集團物業管理服務的收益約為人民幣15.9百萬元（2023年：人民幣15.4百萬元）。物業管理服務收益小幅增加是由於餐廳業績的改善。於2025年12月31日，本集團管理的總建築面積為72,534平方米。投資物業本集團的投資物業主要包括擁有或按租賃權益持有以賺取租金收入及╱或資本增值的土地及╱或樓宇。於2025年12月31日，投資物業的公允價值為人民幣979.0百萬元（2024年：人民幣967.1百萬元），較去年增加約1.23%。截至2025年12月31日止年度，投資物業的估值收益約為人民幣10.3百萬元（2024年：約人民幣6.6百萬元）。展望世界銀行表示，儘管貿易緊張局勢持續存在，但全球經濟展現出比預期更強的韌性。面對外部壓力及內部困難增多的複雜形勢，中國持續推進高品質發展，經濟運行總體平穩、穩中有進。隨著經濟的穩定增長，企業對商業空間的需求增加，加上城市化促使新商業區域的開發，進一步帶動對商業物業的需求上升，這有助推動商業物業管理及租賃的發展。中國政府針對商業地產採取了以消化存量、優化產業佈局為核心的優惠政策，也為物業管理及租賃行業的發展提供支援。本集團旗下管理的物業主要為商用物業，受宏觀經濟及市場競爭等因素影響，在2025年，租戶及租務合同、出租率雖然保持穩定。但是，新簽訂租金水平較此前有所下降。為了應對租金下調的壓力，集團未來將繼續通過在新租約中增加增值服務如物業維護與保養、設施管理、及社區活動策劃，以提升客戶滿意度。集團現有物業主要集中於四川成都和雲南昆明兩大核心城市，借助優越的地理位置和高品質的物業，吸引了大量國有企業及大型機構的入駐，為租賃業務打下了堅實的基礎。近年來，集團已成功引進新興行業租戶，如軟體和科技行業，並為租戶提供數位化服務。未來，集團將推動業務多元化發展，致力吸引更多優質的商戶入駐。另外，2026年3月中東局勢的進一步升溫導至的能源價格上升、通膨預期推高、經濟增長放緩等，均影響海外投資決策的核心因素。因此，集團在海外投資方面的計劃，將會重新審慎評估其資產配置與區域風險。儘管當前全球經濟波動較大，集團將堅持穩健原則，靈活把握投資視窗，確保資本運作的安全性。集團積極運用科技，推動智慧物業建設，提升運營效率和客戶體驗，增強物業管理的智慧化和精細化水準，提升整體服務品質和客戶滿意度。集團將繼續充分發揮與母公司中國光大集團的協同效應，積極拓展多元化增值服務，豐富收入結構，提升品牌影響力。面對行業轉型升級，集團堅持穩健經營，注重風險管理和內部控制，靈活應對宏觀經濟及政策變化，持續優化資產組合，增強抗風險能力，並將在穩健經營的基礎上，積極探索新的發展機遇，為股東創造更大的價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 國元國際發表於3月24日研究報告表示，億勝生物科技（1061.HK）2025年業績穩健增長，實現營業額18.14億港元，較2024年增加8.6%，主因眼科與外科板塊持續發力。其中，眼科收入達8.35億港元（+8.2%），外科收入8.96億港元（+1.8%），醫療保健服務收入激增350%至0.829億港元。億勝生物科技2025年溢利較2024年增加3.5%至3.18億港元。毛利率為89.2%，處行業高位。現金及等價物增至7.83億港元（+40.5%）。公司實施中期股息每股7港仙，末期股息擬派每股7港仙，合計每股派息14港仙，較2024年每股12港仙增長16.7%。2025年，億勝生物科技的國際化戰略取得成果，並不斷擴大對外合作。旗下貝復舒®已通過新加坡特別採用程式成功引入新加坡國家眼科中心，此里程碑標誌產品首次進入中國以外地區，為未來在東南亞及全球市場推出奠定基礎。此外，貝伐珠單抗BLA已獲受理，前景廣闊；而公司從Mitotech獲得SkQ1滴眼液全球獨家權益，能把握乾眼症市場的龐大巿場空間。國元國際表示，公司原有業務穩健增長，能提供較好的現金流，新產品貝伐珠單抗三期臨床試驗達到主要臨床終點，該產品的國內以及海外市場空間廣闊，隨著創新藥未來商業化順利推進，將推動公司業績上升。目前靜態PE僅為6.5倍，價值低估，建議積極關注。重要披露： 本文引用國元國際控股有限公司於2026年3月24日發表的研究報告內容。本資料僅供參考，不構成投資建議，投資有風險，請謹慎決策。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

AALBORG, DENMARK AND MELBOURNE, AU, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - The North Jutland technology company NanoNord has, in connection with the Royal Couple's state visit to Australia, secured an order for additional measurement equipment valued at between 160k - 240k AUD from the Australian deeptech pioneer ElectraLith. The order underscores the growing international potential for Danish measurement technology in the green transition.NanoNord was part of the business delegation during the state visit and seized the opportunity to strengthen its business with both existing and new customers in Australia. It is not the first time the Danish Royal Family has been close to NanoNord - the company was originally officially inaugurated by a then-young Crown Prince Frederik.Danish Technology Measures Lithium in Real TimeNanoNord's flagship technology, Tveskaeg, is an MR-based measurement instrument that enables precise real-time measurement of lithium and a range of other elements. The technology is wireless, uses neither chemicals nor disposable materials, and requires minimal calibration and maintenance - making it robust, green, and operationally reliable.ElectraLith uses Tveskaeg instruments as a central part of their groundbreaking DLE-R technology for lithium extraction. DLE (Direct Lithium Extraction) is a new and far more sustainable method for extracting lithium - a critical metal in the batteries powering the green transition. The full potential of the collaboration is up to DKK 10 million over the coming years, as ElectraLith rolls out its technology globally.The two companies connected in Melbourne during the Danish Industry reception 'An Evening in the Name of Business, Sport and Danish Dynamite,' and further strengthened ties during a meeting at ElectraLith's headquarters following the conclusion of the official business delegation.A Happy Customer on the Other Side of the Globe"Tveskaeg is an essential part of our DLE-R system and we are delighted with our partnership with Martin and the NanoNord team. Each DLE-R unit will include a Tveskaeg system to measure lithium and the order of additional units highlights its importance to our operations, particularly as we prepare for rapid global deployment to meet burgeoning demand lithium.Our existing two systems perform flawlessly and intuitively - so much so that our team has named them Forky and Hilda (after King Sweyn ‘Forkbeard' Tveskaeg and his wife). This is our second major order, in what we expect to be many."- Charlie McGill, CEO, ElectraLith"There is nothing better than visiting a customer on the other side of the globe and seeing our technology in use with happy customers like Charlie and his team. Our talented employees back at Skjernvej in Aalborg deserve the credit for the technology simply working and the customers being happy. That we can also bring home an order for additional instruments naturally makes me extra pleased."- Martin Mindorf, CCO, NanoNord"It is a great honour to be part of the historic state visit to Australia, and we are honoured by the attention from especially H.M. the Queen on this trip. The Queen quickly understood the potential of the technology in Australia and asked curiously about how Tveskaeg is used in connection with lithium extraction. NanoNord and ElectraLith are a great example of how our countries can work together, and there is great potential out here, particularly for the extraction of metals that are critical for the green transition. Beyond ElectraLith, we also have several exciting customers and prospects that we need to come back for."- Martin Mindorf, CCO, NanoNordAbout ElectraLithElectraLith is an American deeptech pioneer developing DLE-R - a proprietary electrochemical technology for lithium extraction and refining. The technology produces battery-grade lithium hydroxide or carbonate without water, chemicals, or waste, and can be powered by renewable energy.In December 2024, the company closed a materially oversubscribed Series A round of approximately USD 17 million with investors including Rio Tinto, Chevron, Marathon Petroleum, and In-Q-Tel. In 2026, ElectraLith was selected a Top Innovator by the World Economic Forum and has pilot projects planned in Australia, the United Kingdom, and Argentina.About NanoNordNanoNord was founded in 2001 by inventor Ole Nørgaard Jensen, who previously sold the Bluetooth pioneer company Digianswer to Motorola. The company develops and manufactures MR-based measurement equipment under the name Tveskaeg, used for applications including sodium measurement in food, lithium measurement in the mining industry, and nitrogen and phosphorus measurement in agriculture. Customers include global names such as Kraft-Heinz, Orkla, and Imerys. In the other industries, such as the food industry, NanoNord equipment eliminates the need for silver nitrate titration, and in several European countries, Tveskaeg technology is currently being tested for agricultural applications, where it has the potential to optimise the use of slurry, resulting in less groundwater pollution and better utilisation of nutrients.NanoNord is foundation- and family-owned, with the Lauritzen Foundation as a major investor, and continues to be led by founder Ole Nørgaard Jensen as CEO. In Australia, NanoNord is represented during the state visit by Martin Nørgaard Mindorf, CCO, the next generation of the family.Contact information:Martin MindorfCCOmm@nanonord.dk+4596341590Charlie McGillCEOcharles.mcgill@electralith.comSOURCE: NanoNord Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麥奧爾堡與澳洲墨爾本, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 北日德蘭半島科技公司NanoNord趁丹麥王室夫婦對澳洲進行國事訪問之際，成功獲得澳洲深科技先驅ElectraLith價值16萬至24萬澳元的額外測量設備訂單。此筆訂單彰顯了丹麥測量技術在綠色轉型領域日益增長的國際潛力。NanoNord 作為國事訪問期間的商業代表團成員，把握良機強化了與澳洲現有及新客戶的業務往來。這並非丹麥王室首次與 NanoNord 結緣——該公司最初正是由當時尚年輕的弗雷德里克王儲正式揭幕成立。丹麥技術實現鋰元素即時測量NanoNord 的旗艦技術「Tveskaeg」是一款基於磁共振（MR）的測量儀器，能精確即時測量鋰及其他多種元素。該技術採用無線傳輸，無需化學藥劑或耗材，且校準與維護需求極低，使其具備堅固耐用、環保及運作可靠的特性。ElectraLith將Tveskaeg儀器作為其突破性鋰提取技術DLE-R的核心組件。DLE（直接鋰提取）是一種嶄新且更具永續性的鋰提取方法——鋰是推動綠色轉型之電池中的關鍵金屬。隨著ElectraLith在全球推廣其技術，雙方合作在未來數年的潛在價值可達1,000萬丹麥克朗。兩家公司於墨爾本舉行的丹麥工業招待會「以商業、體育與丹麥動能之名之夜」上建立聯繫，並在官方商務代表團結束後，於 ElectraLith 總部舉行的會議中進一步鞏固了合作關係。地球另一端的滿意客戶「Tveskaeg 是我們 DLE-R 系統不可或缺的一部分，我們非常高興能與 Martin 及 NanoNord 團隊合作。每台 DLE-R 設備都將配備 Tveskaeg 系統來測量鋰含量，而此次追加訂購的數量更凸顯了該系統對我們營運的重要性，特別是在我們正準備進行快速全球部署以滿足鋰需求激增之際。我們現有的兩套系統運作無懈可擊且直覺易用——甚至讓我們的團隊為它們取名為 Forky 和 Hilda（取自「叉鬍子」斯文·特維斯卡格國王及其妻子的名字）。「這是我們收到的第二筆重大訂單，而我們預期未來還會有更多。」——查理·麥吉爾（Charlie McGill），ElectraLith 執行長「沒有什麼比造訪地球另一端的客戶，並親眼見證我們的技術被像查理及其團隊這樣的滿意客戶所採用更令人欣慰的了。這項技術能順利運作且讓客戶滿意，功勞全歸於我們在奧爾堡（Aalborg）斯凱恩韋（Skjernvej）總部才華洋溢的員工。「我們還能為公司帶來額外的儀器訂單，這自然讓我格外高興。」——馬丁·明多夫（Martin Mindorf），NanoNord 首席商務官「能參與這次歷史性的澳洲國事訪問是莫大的榮幸，我們尤其榮幸在此次行程中獲得女王陛下對我們的關注。女王迅速理解了這項技術在澳洲的潛力，並好奇地詢問了 Tveskaeg 如何應用於鋰礦開採。NanoNord 與 ElectraLith 正是兩國合作典範，此地蘊藏巨大潛力，特別是在綠色轉型所需的關鍵金屬萃取領域。除了 ElectraLith 之外，我們還有數家令人振奮的客戶與潛在合作對象，這正是我們必須再次造訪的原因。」- 馬丁·明多夫（Martin Mindorf），NanoNord 首席商務官關於 ElectraLithElectraLith 是一家美國深科技先驅企業，致力於開發 DLE-R——一種專有的電化學技術，用於鋰的萃取與精煉。該技術能在不使用水、化學品或產生廢棄物的情況下，生產電池級氫氧化鋰或碳酸鋰，且可由可再生能源驅動。2024年12月，該公司完成了一輪約1,700萬美元的A輪融資，認購額遠超預期，投資方包括力拓（Rio Tinto）、雪佛龍（Chevron）、馬拉松石油（Marathon Petroleum）及In-Q-Tel。2026年，ElectraLith獲選為世界經濟論壇「頂尖創新者」，並計劃在澳洲、英國及阿根廷開展試點項目。關於 NanoNordNanoNord 由發明家 Ole Nørgaard Jensen 於 2001 年創立，他此前曾將藍牙先驅公司 Digianswer 出售給摩托羅拉。該公司以 Tveskaeg 為品牌名稱，開發並製造基於磁共振（MR）技術的測量設備，應用領域包括食品中的鈉含量測量、採礦業中的鋰含量測量，以及農業中的氮磷含量測量。客戶包括卡夫亨氏（Kraft-Heinz）、奧克拉（Orkla）及伊美瑞斯（Imerys）等全球知名企業。在食品等其他產業中，NanoNord 的設備消除了對硝酸銀滴定法的依賴；在多個歐洲國家，Tveskaeg 技術目前正針對農業應用進行測試，該技術有望優化液態肥料的使用，從而減少地下水污染並提升養分利用率。NanoNord 為基金會與家族共同持有，主要投資者為勞瑞岑基金會（Lauritzen Foundation），並持續由創辦人 Ole Nørgaard Jensen 擔任執行長領導。在澳洲，NanoNord 由家族新世代成員、首席商務長（CCO）Martin Nørgaard Mindorf 代表出席此次國事訪問。聯絡資訊：Martin Mindorf首席商務長（CCO）mm@nanonord.dk+4596341590查理·麥吉爾 (Charlie McGill)執行長charles.mcgill@electralith.com消息來源：NanoNord Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 25, 2026) - Adyton Resources Corporation (TSXV: ADY) ("Adyton" or the "Company") is pleased to announce positive expansionary drill results from its ongoing exploration program at the 100% owned Feni Island Gold-Copper Project, located on the productive Lihir Trend, Papua New Guinea (PNG). This announcement provides all the assay results for expansionary hole FDD017 (preliminary results were first reported on February 18, 2026).Hole FDD017 previously returned 53m @ 1.29g/t Au (gold only) and now, incorporating newly released copper assays, reports as 53m @ 1.60g/t AuEq representing an approximate 25% increase in reported grade. In addition, strong silver (Ag) and molybdenum (Mo) results further support the presence of a highly fertile epithermal-porphyry at Kabang.KEY HIGHLIGHTS OF DRILL HOLE FDD017Final assays for hole FDD017 have delivered another >100g*m intercept, further confirming strong Au-Cu mineralisation in the north-eastern extension targetHole FDD017 yielded:53m @ 1.29g/t Au, 0.26% Cu (1.60g/t AuEq; from 151m)within a broader interval of 164m at 0.63g/t Au, 0.15% Cu (0.82g/t AuEq for 134g*m; from 36m);including a higher-grade interval that returned: 5m @ 3.6g/t Au, 1.48% Cu (5.63g/t AuEq: from 198m)In addition to gold and copper, FDD017 also reports significant silver and molybdenum signalling strong system fertility for a large alkalic epithermal-porphyry system:5m @ 22.3g/t Ag (from 198m) and 6m @ 275ppm Mo (from 295m; peak Mo 579ppm)These final assay results for hole FDD017 confirm the North-Eastern zone at Kabang is strongly mineralised and prospective for gold and copper and continues to expand this zone beyond the current resource model.Ground based IP/MT survey progressing well; looking to deploy within 2Q 2026."FDD017 continues to exceed our expectations, delivering a meaningful uplift in grade with the inclusion of copper and highlighting the strength of the broader mineralized system at Feni. The increase to 1.60g/t AuEq over 53 metres, combined with strong silver and molybdenum values, reinforces our view that Kabang represents a highly fertile and evolving epithermal-porphyry system. Importantly, this hole further confirms the scale and continuity of mineralization in the north-eastern extension, which remains open and continues to grow beyond the current resource footprint." said Tim Crossley, CEO.Adyton is looking forward to receiving additional assays from nearby drillholes within this zone and updating the market accordingly.SIGNIFICANT INTERCEPTSTable 1 shows the Significant Intercepts for gold and copper assay results received to date (new assays this release for FDD017 only). Figures 1, 2, 3 and 4 show plan map and cross/long sections. See previous release for Table 2 - drillhole status (Feb 18, 2026 news release).Table 1: Gold and Copper Significant Intercepts from Adyton's 2021 (ADK) and 2025/2026 (FDD) drilling at the Feni Island Au-Cu Project (gold, copper and gold equivalent). See footnotes to table: 1 2 3 4To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_001full.jpgFigure 1: Feni Project (inset: located on the +120MozAu Lihir Island gold trend), showing Kabang MRE (centre) and numerous, highly prospective, additional target opportunities at Feni. Upcoming IP/MT survey outline highlighted.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_002full.jpgFigure 2: Plan view of the Kabang Au-Cu deposit with Significant Intercepts on drill traces (noting numerous drillholes pending assays), with re-processed mag and IP anomalies. The dashed red arcuate line outlines the extent of anomalous Mo and is interpreted to denote the porphyry mineralization footprint based on drilling to date. The green arrow is the vector towards epithermal mineralization based on As-Sb pathfinder elements increasing to the SSW. Pending assays and future drilling will increasingly allow the company to hone-in on porphyry-related and epithermal-related Au-Cu mineralization.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_003full.jpgFigure 3: Cross section of hole FDD017 with geology and assays. It highlights the consistent Au-Cu mineralization as punctuated by high-grade gold-copper intercepts within an extensive monzonite/intrusive breccia mineralized zone unit from 36m to 220m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_004full.jpgFigure 4: This long section utilizing recently reprocessed mag and IP data shows the now apparent close correlation of the Danmagal porphyry system evidenced at depth by magnetics data (red polygon >0.16MVI) and the close spatial relationship of the Kabang epithermal system (orange 27mRad IP anomaly) and known gold grades. Of note, geochemical zonation appears to be vectoring towards a hydrothermal fluid source to the SW and to depth - exactly where the Danmagal porphyry is located. Furthermore, the Kabang drilling has encountered smaller apophyses of porphyry style intrusives and copper mineralization, and the current geological model suggests that Danmagal is the likely source of these.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_005full.jpgFUTURE CATALYSTS & OUTLOOKAdyton is well-funded with C$16.75m in cash and cash equivalents, 100% earmarked for the Feni Au-Cu Project (plus G&A). The company is executing a systematic exploration strategy to grow the MRE and discover new deposits. Upcoming results and milestones include:Pending Assays:NNE: FDD018, FDD020, FDD023, FDD025, FDD029SSW: FDD019, FDD021, FDD024, FDD026, FDD028Ongoing Drilling: focused on expanding the MRE footprint at Kabang, and testing new targets.Advanced Geophysics: An approximately 5km by 5km ground-based IP & MT survey is being scoped to detect additional deposits on Feni Island and detect deeper prospective targets for drilling (see Figure 1).Spectral Mapping: Deployment of pXRF as well as spectral mineral mapping (1Q 2026) to generate a 3D alteration model for precise vectoring toward the core of the mineralized system with potential high Au-Cu grades to target for drilling.FERGUSSON ISLAND PROGRESS UPDATEEVIH, our 50/50 JV partner, continues to make good progress on the restart of the Wapolu Au Mine. Key areas of significant progress include purchasing and shipping of long lead items and processing plant components. The Mineral Resources authority have also set the date for the ML application Wardens Hearing for May 21, 2026. It is expected that, subject to permitting, Wapolu could be in production in Q4 2026. Adyton does not have any capital expenditure requirements for the Wapolu, these are being provided by EVIH as part of the JV earn-in to the Fergusson projects.QUALITY ASSURANCE / QUALITY CONTROLAdyton adheres to industry-recognized standards of Best Practice and Quality Assurance/Quality Control (QA/QC). Drill core samples were submitted in batches to Intertek Laboratory in Lae, which include a field blank, certified reference materials (CRMs) and staged duplicates. Samples were sealed ensuring Chain of Custody. To date, all batches have passed QA/QC, and blanks and CRMs were within acceptable tolerance limits. All drill holes were drilled and sampled predominantly from PQ and HQ diameter drill core, and to a lesser extent, also NQ core. Core recovery is considered to be appropriate.Qualified PersonThe scientific and technical information contained in this press release has been prepared, reviewed, and approved by Dr Chris Bowden, PhD, GCMEE, FAusIMM(CP), FSEG, the Chief Operating Officer and Chief Geologist of Adyton, who is a "Qualified Person" as defined by National Instrument 43‐101 ‐ Standards of Disclosure for Mineral Projects.ABOUT THE FENI GOLD-COPPER PROJECTThe Feni Project is 100% owned by Adyton and is a key asset in Adyton's portfolio, located in a highly prospective region of Papua New Guinea on the Lihir Island chain known for world-class gold-copper deposits, including Lihir (owned and operated by Newmont). The Company has confirmed significant gold-copper mineralization at Feni, with a focus on expanding its existing resource and identifying new high-grade targets.For further information please contact:Tim Crossley, Chief Executive OfficerE‐mail: ir@adytonresources.comPhone: +61 7 3854 2389Phone: +1 778 549 6768Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.ABOUT ADYTON RESOURCES CORPORATIONAdyton Resources Corporation is focused on advancing gold and copper projects in world-class mineral jurisdictions. The Company holds a portfolio of highly prospective assets in Papua New Guinea where it is actively working to expand its existing gold Inferred and Indicated Mineral Resources and build on recent high-grade gold and copper drill results at its 100% owned Feni Island ‎project.Adyton's projects are located on the Pacific Ring of Fire, on accessible island settings that host several globally significant deposits including the Lihir gold mine and ‎Panguna copper-gold mine on Bougainville Island, both in close proximity to Feni, highlighting the district-scale potential of the Company's land package.Feni Island Au-Cu projectThe Feni Island Project currently has a mineral ‎resource prepared in accordance with NI 43-101 dated October 14, 2021, which has outlined an initial inferred ‎mineral resource of 60.4 million tonnes at an average grade of 0.75 g/t Au, for contained gold of 1,460,000 ounces, ‎assuming a cut-off grade of 0.5 g/t Au. See the NI 43-101 technical report entitled "NI 43-101 Technical Report on the Feni Gold-Copper Property, New Ireland ‎Province, Papua New Guinea prepared for Adyton Resources by Mark Berry (MAIG), Simon ‎Tear (MIGI PGeo), Matthew White (MAIG) and Andy Thomas (MAIG), each an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under Adyton's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.Fergusson Island Au projectThe Fergusson Island Project currently has a mineral resource prepared in accordance with NI 43-101, which outlined an indicated mineral resource of 5.0 million tonnes at an average grade of 1.28 g/t Au for contained gold of 206,000 ounces and an inferred mineral resource of 23.2 million tonnes at an average grade of 0.99 g/t Au for contained gold of 733,000 ounces, both inferred and indicated resources used a 0.5g/t Au cut-off grade.See the technical report dated October 14, 2021, entitled "NI 43-101 Technical Report on the Fergusson Gold Property, Milne Bay ‎Province, Papua New Guinea" prepared for Adyton Resources by Mark Berry (MAIG), Simon ‎Tear (MIGI PGeo), Matthew White (MAIG) and Andy Thomas (MAIG), each an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under the Company's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.See the technical report dated January 7, 2026, entitled "NI 43-101 Technical Report on Wapolu Gold Project" prepared for Adyton Resources by Louis Cohalan (MAIG), an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under the Company's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.For more information about Adyton and its projects, visit www.adytonresources.comTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_adytonmap0103052026.jpgForward-looking statementsThis press release includes "forward‐looking statements", including forecasts, estimates, expectations, and objectives for future operations that are subject to several assumptions, risks, and uncertainties, many of which are beyond the control of Adyton. Forward‐ looking statements and information can generally be identified by the use of forward‐looking terminology such as "may", "will", "should", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward looking statements in this news release include plans pertaining to the drill program, the intention to prepare additional technical studies, the timing of the drill program, uses of the recent drone survey data, the timing of updating key findings, the preparation of resource estimates, and the deeper exploration of high-grade gold and copper feeder systems. The forward‐looking information contained herein is provided for the purpose of assisting readers in understanding management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.Forward‐looking information are based on management of the parties' reasonable assumptions, estimates, expectations, analyses, and opinions, which are based on such management's experience and perception of trends, current conditions and expected developments, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future development of the projects in a timely manner; the availability of financing on suitable terms for the development; construction and continued operation of the Fergusson Island Project and the Feni Island Project; the ability to effectively complete the drilling program; and Adyton's ability to comply with all applicable regulations and laws, including environmental, health and safety laws.Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect Adyton's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of managements considered reasonable at the date the statements are made. Although Adyton believes that the expectations reflected in such forward- looking statements are reasonable, such information involves risks and uncertainties, and under reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements expressed or implied by Adyton. Among the key risk factors that could cause actual results to differ materially from those projected in the forward- looking statements are the following: impacts arising from the global disruption, changes in general macroeconomic conditions; reliance on key personnel; reliance on Zenex Drilling; changes in securities markets; changes in the price of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave‐ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of and changes in the costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward‐looking statements. Such forward‐looking information represents management's best judgment based on information currently available. No forward‐looking statement can be guaranteed, and actual future results may vary materially. Readers are cautioned not to place undue reliance on forward looking statements or information. Adyton Resources Corporation undertakes no obligation to update forward‐looking information except as required by applicable law.1 Interval widths are "apparent" widths downhole, subject to true width determination.2  ADK series drilling (2021) reported previously to TSX.V. Au.eq recalculated here.3 Gold equivalent calculated as: Au.eq = ((Au g/t *0.93) + (Cu% *1.71 * 0.90)). Based on: metal prices of US$2,000/oz Au and US$5/lb Cu; and recoveries of 93% Au and 90% Cu. Recovery assumptions are speculative as no metallurgical test work have been completed at Feni but are based on comparable deposits.4 FDD002 & FDD004 ended in mineralisation.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289847 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com